ResMed Inc. (CHESS) earnings preview: What investors can expect

Sleep treatment specialist ResMed Inc. (CHESS) (ASX:RMD) will release its earnings for the 2nd quarter of the 2018 financial year after the NYSE trading session closes tomorrow morning.

ResMed delivered another excellent operational result for the September 2017 quarter with revenues rising 13% to $US524 million (11% at constant currency). Earnings per share (GAAP) rose 11% over the prior period to $US0.60. The company’s share price rose strongly following the result with the Australian scrip rising from $10.15 on October 26 to an all time high of $11.49 on December 11. However, a minor sell off occurred following ResMed’s arch-rival Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) announcing that it had filed patent infringement proceedings against ResMed in Australian courts.

Q2 expectations

Currently, U.S. analysts’ earnings per share forecasts for the December quarter range from a high of 81 cents a share, to a low of 75 cents a share, with the average consensus being 78 cents a share.

ResMed is expected to continue to perform strongly in both its established and developing markets. During the September quarter, the company saw revenues in the Americas, excluding its Brightree software segment, grow 11% to $US297 million.  The Brightree segment which provides cloud-based software to improve clinical and business performance saw its revenues rise by 15% to $US38 million. Revenue in the combined Europe, Middle East, Africa and the Asia Pacific region rose by 11% on a constant currency basis to $US189 million.  ResMed remains one of the leaders in treating sleep apnea and the strong growth in sleep apnea patient volume has seen sales for the company’s devices, masks and software continually rise. The developing world, in particular China and India remain large markets with low levels of sleep apnea treatments that a company such as ResMed can provide solutions for.

Whilst ResMed’s primary NYSE listing has seen the stock prick price climb to all time highs in 2018, ASX shareholders have not benefitted as the appreciation of the Australian Dollar has outweighed the positive price movements on the U.S. market. ResMed remains one of the best Australian healthcare businesses with a global focus but is far from cheap trading around 28 times projected FY18 earnings. If the company is unable to meet the market’s expectations (see June 17 quarter) a minor selloff would provide investors with a more compelling entry point from a valuation perspective.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool Contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.